Fulcrum therapeutics® reports inducement grants under nasdaq listing rule 5635(c)(4)

Cambridge, mass., july 15, 2022 (globe newswire) -- fulcrum therapeutics, inc. (nasdaq: fulc), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to new employees as inducement awards outside of the company's 2019 stock incentive plan. fulcrum granted stock options to purchase an aggregate of 33,620 shares of the company's common stock to five new employees. the awards were granted as of july 11, 2022, pursuant to the company's 2022 inducement stock incentive plan, each as an inducement material to the new employees entering into employment with the fulcrum therapeutics in accordance with nasdaq listing rule 5635(c)(4).
FULC Ratings Summary
FULC Quant Ranking